Company* | University/ | Type Of | Product Area | Details (Date) |
| | ||||
Acacia Research Corp. (ACRI) | Research Center for Advanced Science and Technology at the University of Tokyo (Japan) | Technology access collaboration and purchasing agreement | To install a Combimatrix gene chip synthesizer | The parties also entered a multi-year deal to purchase blank chips to aid in development of diagnostic microarray applications, drug lead development and target gene identification (5/30) |
Advanced | Defense Advanced Research Projects Agency | Eight-month contract | To initiate studies to develop immune system research models | Contract is worth $3M (8/1) |
Advanced Biotherapy | Department of Energy's Pacific Northwest National Laboratory | Cooperative research and development agreement | For a project titled "Anti-Cytokine Antibodies for Treating Immune- Mediated Diseases" | The agreement is for the development of high-affinity humanized antibodies to gamma interferon (6/3) |
Ambion Inc.* | Harvard Medical School | Worldwide nonexclusive licensing agreement | For a patent application covering a mammalian small interfering RNA expression vector | Financial terms were not disclosed (7/23) |
American Biogenetic Sciences Inc. | Russian Federation Mexico, the countries of Central and South America and the People's Republic of China | Exclusive distribution agreement | To distribute an oral smallpox vaccine in the U.S., Canada, | The company is seeking partners to test, market and distribute the vaccine (6/6) |
Amersham Biosciences | Sloan-Kettering Institute | Two-year collaboration | For the Functional Proteomics Project | The project was established to develop the first technology to scan the entire expressed human genome in a day to test each gene for its function in a cellular process (7/29) |
Atlantic Technology Ventures Inc. (OTC BB: | The inventors of ATV-02 | Licensing agreement | ATV-02, an antimicrobial agent for the local treatment of topical infections | Terms of the deal were not disclosed (7/9) |
AxCell | National Cancer Institute | Cooperative research and development agreement | To research TEY1, a newly discovered metastasis suppressor gene for prostate | The NCI will provide biological and biochemical information on the TEY1 gene and its protein, while AxCell will provide SH3 domain interaction data from its ProChart database to identify the protein or proteins that inter- act with the TEY1 protein (6/18) |
AxCell | National Cancer Institute | Cooperative research and development agreement | To apply AxCell's | AxCell will have an exclusive option for a commercialization license to all inventions, such as drug candidates and new methods of screening (7/17) |
Beyond Genomics | Boston University School of Medicine | Strategic research alliance | To establish | BUSM will provide access to its research faculty and clinical experts, while Beyond Genomics will provide access to its systems biology technologies and drug discovery research capabilities (5/23) |
Biokeys | National Institutes | Exclusive worldwide sublicensing agreement | For U.S. Patent No. 5,562,905, which complements patents | Biokeys will use the patents and technology to develop BlockAide/CR, an HIV viral entry inhibitor (7/8) |
Bioplex Corp.* | Indiana University | Licensing agreement | Technology for the synthesis of optically encoded microbeads and nanobeads for human health applications | The technology will be used for drug discovery and clinical diagnostics (5/21) |
ComGenex | New York Blood Center | Extended collaboration | For an ADME/Tox optimization, synthesis and screening effort for generating therapeutic agents suitable for HIV treatment | ComGenex will be responsible for ADME/Tox and medicinal lead optimization, as well as chemistry; the center will per- form screening activities; any commercial results of the collaboration will be shared (6/27) |
Diversa Corp. | Marine Bioproducts Engineering Center at the University of Hawaii at Manoa | Biodiversity access and research collaboration agreement | For the right to discover genes from existing material collections and from environmental samples | Samples will be collected by the university in and around Hawaii with the intent of commercializing resulting products; financial terms were not disclosed (6/4) |
Dyax Corp. | University | Exclusive rights agreement | To a cancer target, an integrin cell surface receptor found in precancerous prostate lesions and in invasive prostate cancer, but not in normal prostate cells | Dyax will use its phage display technology to identify human antibodies and peptides that specifically bind to the target (7/11) |
Elixir Pharma- | Massachusetts Institute of Technology | Licensing agreement | To patents and patent applications that relate to founding scientist Lenny Guarente's discoveries | The discoveries are associated with longevity and the SIR-2 (silent information regulation) gene (6/3) |
EpiTan Ltd. | Southern Research Institute | Collaborative agreement | To develop a sustained-delivery formulation of Melanotan for use in EpiTan's clinical trial program | Financial terms were not disclosed (6/6) |
Exegenics Inc. | University of California and the University of British Columbia (Canada) | Commer- | To use enzyme targets that can serve in the development of drugs to fight tuberculosis | Research on the enzymes demonstrated a direct correlation between depletion of mycothiol and a susceptibility to antibiotics (6/28) |
Exhale | Brigham and Women's Hospital | Licensing agreement | For intellectual property related to the use of hyaluronic acid to prevent group A streptococcal pharyngitis | Financial terms were not disclosed (7/30) |
FeRx Inc.* | National Cancer Center Research Institute (Japan) | Research collaboration | To develop a tumor- targeting gene transfer approach using FeRx's magnetic targeted carrier drug delivery technology | A variety of genetic vectors, including plasmid DNA, adenoviruses and antisense oligonucleotides, will be studied and combined with the FeRx MTC technology (6/24) |
Genetix Group | Medical Research Council's Human Genome Mapping Project Resource Center (UK) | Collaboration | To develop equipment and systems to quicken the process of identifying the role of proteins in human health and disease | The collaboration is worth 2.5M (US$3.9M), funded by the British Department of Trade and Industry as well as both participants; it is aimed at generating maps to reveal different protein interactions (7/22) |
Genteon Inc.* | Institute for Genetic Medicine at the Keck School of Medicine of the University of Southern California | Research collaboration | To develop methods for studying cancer genetics | The university team will use Genteon's Capella 400 Genetic Analysis System to study genetic mutations and the regulation of gene expression associated with certain cancers (7/18) |
Hydro Med Sciences Inc.* | Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic | Agreement | To provide Hydro Med the option to acquire worldwide development and commercialization rights to a polymer system | The institute will complete certain preclinical studies for Hydro; financial terms were not disclosed (6/10) |
Illumina Inc. | University of North Carolina Pulmonary and Cystic Fibrosis Research Center | Commercial agreement | To provide single nucleotide polymorph- ism genotyping services on a sample collection provided by the center | Illumina will design functional assays for many of the SNP loci provided by the center, then use its BeadArray technology to genotype specified SNPs in the sample set (5/31) |
Illumina Inc. | Wellcome Trust Sanger Institute (UK) | Agreement | To provide single nucleotide polymorph- ism genotyping services on a SNP collection provided by the Wellcome Trust | Illumina will develop assays for the SNP collection and use its BeadArray technology to genotype SNPs (7/24) |
Invitrogen | Columbia | Licensing agreement | For specific Chinese hamster ovary cell lines useful in drug discovery research and in the bioproduction of therapeutic proteins | The license covers the sale of dhfr-negative CHO cells for research use only, but not the media used to maintain and grow those cells (5/22) |
IP Genesis | Baylor College of Medicine | Nonexclusive licensing agreement | For IP's Comparative Sequence Assembly technology | The technology helps decipher the function of the human genome by determining sequences that are conserved across species and stand out among the majority of highly variable junk DNA (7/8) |
Large Scale | Institute of | Collaboration | For the development and manufacture of vaccines intended to protect against infectious diseases | The vaccines will be developed for HIV and human papillomavirus, among others (7/9) |
Large Scale | National Institute | Five-year contract agreement | For work performed at Large Scale's proteomics facility for the National Center for Toxicogenomics | Large Scale will use its ProGEx protein expression analysis technology in the effort, and is expected to analyze a number of samples each year (7/24) |
Large Scale | National University | Collaborative research agreement | For Large Scale's Plurigen CM stem and progenitor cell cultivation product | Initial studies will focus on enhancing proliferation of human peripheral blood stem cells, umbilical cord blood stem cells and mesenchymal stem cells in vitro with the aid of Plurigen (6/14) |
Lorus | National Cancer Institute | Supply agreement | For Lorus' lead anti- sense drug, GTI-2040, for multiple clinical trials to evaluate its efficacy in a range of cancers | Lorus and the NCI will select cancer indications and suitable development programs for trials the NCI will sponsor with GTI- 2040 alone or in combination with other therapies; Lorus will manufacture and provide drug for all trials (6/18) |
Lynx | Institute for | Collaboration | To study prostate cancer gene expression | The agreement features the application of Lynx's Massively Parallel Signature Sequencing technology to uncover differentially expressed genes in prostate cancer; financial details were not disclosed (5/21) |
Lynx | Ludwig Institute for Cancer Research | Service agreement | To study cancer gene expression | Lynx will receive payments for genomics discovery services it will perform on cancer samples provided by the institute (7/18) |
MacroGenics | University of Texas Southwestern Medical Center | Agreement | To establish a MacroGenics research site in Dallas for infectious disease target identification and development of new methods for genetic immunization | MacroGenics is licensing a patent portfolio from the medical center related to new vaccine antigens, adjuvants and methods of immunization (6/6) |
MerLion Pharmaceuticals | Johns Hopkins Singapore Pte. Ltd. (Singapore) | Research and development agreement | Related to Epstein-Barr virus-related cancers | Parties will develop a high- throughput assay based on Johns Hopkins research in viral DNA binding proteins; they will share in development and commercialization (7/25) |
MerLion Pharmaceuticals | National Cancer Center Research Institute (Japan) | Agreement | To screen for compounds that can activate a new tumor-suppressing protein | The NCC will further characterize resulting compounds; all three parties, including Biotech Research Ventures Pte. Ltd., will share an undisclosed portion of benefits from resulting drugs discovered under the collaboration (7/8) |
Mindset Bio- | New York University School | Agreement | To license a vaccine technology for the treatment of Alzheimer's disease | Mindset becomes the worldwide exclusive licensee of the vaccine technology, Amyrex (7/22) |
Molecular | University of California at San Francisco | Collaboration | To investigate the effects of interferon beta therapy on multiple sclerosis patients | Researchers are investigating the effect of interferon beta-1b in MS patients and healthy individuals (6/5) |
Nanogen Inc. | Centers for Disease Control and Prevention | Development site agreement | To install a NanoChip molecular biology workstation at the CDC's foodborne and diarrheal diseases branch in Atlanta | Nanogen will receive certain licensing and commercialization rights to the assays developed by the CDC (6/6) |
Nanogen Inc. | NASA's Ames Research Center | Collaboration | To provide a Nano- Chip Molecular Biology Workstation to NASA in exchange for commercialization rights to NASA- developed intellectual property and assays | NASA will use the Nanogen platform to develop and validate protocols for specific single nucleotide polymorphism and short tandem repeat analyses related to mission requirements (6/12) |
NeoGenesis | Massachusetts General Hospital | Development agreement | To discover and develop drugs that target cancer and inflammatory diseases | Financial terms were not disclosed (7/23) |
Oxford | Cystic Fibrosis Foundation Therapeutics Inc. (a nonprofit affiliate of the Cystic Fibrosis Foundation) | Research collaboration | To discover and validate serum biomarkers of cystic fibrosis and associated pulmonary complications | OGS will apply its industrial- scale proteomics technology to analyze clinical samples collected by the University of North Carolina at Chapel Hill to identify serum proteins that predict early CF lung disease; the foundation will pay up to US$5.5M, including an up-front technology access fee (7/12) |
Panacea Pharm- | Rhode Island Hospital and Brown University | Collaborative research agreement | For the development of drugs to prevent and treat oxidative stress- induced neurodegeneration in a number of conditions | The agreement provides an option that would grant an exclusive worldwide license to Panacea for discoveries made through the collaboration (6/27) |
Proneuron Biotechnologies | Craig Hospital | Collaboration | To continue the development of Proneuron's macrophage cell therapy for treatment of spinal cord injuries | The collaboration includes the establishment of the first Pro- neuron Cell Center in the U.S. (6/24) |
Regma Bio | Institut Pasteur (France) | Research agreement | To develop phage therapies in response to antibiotic resistance, particularly against Mycobacterium tuberculosis | Financial terms were not disclosed (6/17) |
Replicon Technologies | University of Alabama at Birmingham Research Foundation | License agreement | For rights to the use of replicon technology in the development of vaccines against infectious diseases and therapeutic vaccines against human cancers | Replicon gains exclusive rights to the commercial use of licensed patents for replicons in the field of human vaccines (6/11) |
Seaphire International | University of Toronto Innovations Foundation (Canada) | License agreement | For exclusive worldwide rights to technology used to create salt-tolerant plants | Research using the technology has developed tomato and canola plants that grow and pro- duce fruit and seeds when irrigated with water that is 33% the salinity level of saltwater (7/17) |
Syngenta AG* (Switzerland) | National Institute of Agrobiological Sciences (Japan) | Agreement | To share the Syngenta rice genome draft sequence data with the International Rice Genome Sequencing Project | The Syngenta contribution is expected to accelerate completion of a finished sequence and reduce overall project costs (5/23) |
Telik Inc. | Arizona Cancer Center | Licensing agreement | To obtain exclusive worldwide rights to intellectual property, including small-molecule drug candidates for four cancer targets | Telik is applying its TRAP drug discovery technology to identify compounds active against cancer targets identified by the Arizona researchers (7/17) |
Variagenics | St. Jude Children's Research Hospital | License agreement | For exclusive rights in the field of oncology to develop diagnostic tests predictive of drug response | The agreement covers a patent application claiming CYP3A5 genotyping methods and diagnostic test kits predictive of variable expression of CYP3A5 (7/26) |
Vical Inc. | Dale and Betty Bumpers Vaccine Research Center and the National Institute of Allergy and Infectious Diseases | Contract | To manufacture clinical-grade supplies of an experimental DNA vaccine against Ebola for initial clinical development | Further details were not disclosed (7/17) |
Viragen Inc. | University of | Development agreement | For anticancer technology | The project is designed to develop a form of an immune-enhancing drug that has shown promise by inhibiting tumor growth in cancers; Viragen also receives an option to acquire an exclusive worldwide license in order to commercialize the technology (7/30) |
Xcyte | University of Pennsylvania | Licensing agreement | To a genetically modified cell line that could be used to activate and grow T cells | The Xcellerate Technology employs proprietary beads that deliver signals required to activate a patient's T cells, which can be used to treat a range of diseases (5/22) |
Xechem International | National Institute | Licensing agreement | For exclusive worldwide rights to a drug product for treating and managing sickle-cell anemia | The product is in Phase III trials in Nigeria (8/1) |
Zyomyx Inc.* | Partners | Strategic alliance | To apply Zyomyx's protein profiling biochip system to clinical research | Zyomyx and Partners will establish a core protein profiling research facility to focus primarily on the identification and validation of protein biomarkers to improve the understanding and diagnosis of complex diseases (6/24) |
| | ||||
Notes: | ||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board | ||||
